- |||||||||| Humira (adalimumab) / AbbVie, Yuflyma (adalimumab-aaty) / Celltrion, Hikma
An Analysis of Stakeholders () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2227; Comparing each stakeholder
- |||||||||| Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Cost-Effectiveness Analysis of Infliximab, Adalimumab, and Certolizumab for Crohn's Disease: A Markov Model Study () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2167; Infliximab emerges as the most cost-effective option for Crohn's disease treatment among the three drugs, staying below the $100,000/QALY threshold and providing the highest QALYs at the lowest cost. The findings are significant for healthcare decision-makers, emphasizing the integration of economic assessments in clinical decisions, particularly in Crohn's disease management.
- |||||||||| Humira (adalimumab) / AbbVie
Medication Adherence, Persistence, and Treatment Switching in Patients Receiving Advanced Therapies for Rheumatoid Arthritis in Clinical Practice () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2151; Adult patients diagnosed with RA, initiating an AT (index; date of first pharmacy claim for upadacitinib, tofacitinib, baricitinib, adalimumab, etanercept, abatacept, or tocilizumab) with recent TNFi experience (?12 months pre-index), and with continuous insurance enrollment for ?12 months pre- and post-index were included. Overall, treatment adherence was significantly higher, and rates of treatment discontinuation or switching were significantly lower for patients initiating upadacitinib compared with other ATs after recent TNFi treatment.
- |||||||||| Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Humira (adalimumab) / AbbVie
Beyond the Headline: Inflation-Adjusting ICER () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1204; However, in routine clini cal practice, c ombining these PROMs with physician We analyzed all instances of
- |||||||||| Humira (adalimumab) / AbbVie
DADA2 Syndrome Causing Cerebrovascular Ischemic Syndromes in Two Asian Siblings (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_4220; Vasculitis as a culprit mechanism is an important consideration in cerebrovascular ischemia, particularly in young patients with suggestive angiographic findings, associated systemic inflammation, or minimal cardiovascular risk factors. Accurate diagnosis of the primary causative syndrome, in these cases DADA2 syndrome, is critical in ensuring patients receive the most efficacious immunosuppressive therapy possible.
- |||||||||| Humira (adalimumab) / AbbVie
Neurosarcoidosis Treated with Adalimumab: A Case Series (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_4064; All patients in our study, who received adalimumab were able to tolerate the therapy without major adverse effects, although increased risk of serious infections was noted. As we continue to refine our understanding of this complex disorder, adalimumab's targeted immunomodulation offers a promising avenue for managing the challenging landscape of neurosarcoidosis treatment.
- |||||||||| Humira (adalimumab) / AbbVie
A Case of Neuro-Behcet's Syndrome Without Genital Ulcers (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_4060; This rare case highlights that the presence of genital ulcers is not mandatory for diagnosing Behcet's diseases, despite being considered the second most common symptom at the time of diagnosis. In situations where patients exhibit neurological symptoms in the setting of recurrent oral ulcers, cutaneous lesions, and recurrent epididymitis, neuro-Behcet's syndrome should be promptly considered despite the lack of genital ulcers.
- |||||||||| Humira (adalimumab) / AbbVie
Autoimmune Limbic Encephalitis in the Setting of TNF-Inhibitor Use for Crohn's Disease (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_3557; Nevertheless, this case highlights the crucial significance of maintaining a vigilant stance toward autoimmune encephalitis, even in the absence of detectable autoantibodies. Timely diagnosis and the immediate initiation of immunotherapy hold the potential to arrest the underlying immunological processes, thereby preventing irreversible brain damage.
- |||||||||| Humira (adalimumab) / AbbVie
What's that Mass? A Sphenoid Lesion Causing Cavernous Sinus Syndrome (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_2612; She has since been stable on adalimumab.Neurosarcoidosis is a diagnosis of exclusion, and a systematic workup is crucial to ensure prompt, proper treatment. It is important for neurology providers to recognize presentation and exam findings for a cavernous sinus mass, understand differential diagnoses and workup for said mass, and be able to facilitate acute and long-term management of neurosarcoidosis.
- |||||||||| Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: High Body Mass Index and Response to Anti-TNF Therapy in Pediatric Crohn Disease. (Pubmed Central) - Mar 6, 2024 Standard adalimumab dosing may be insufficient for overweight children with PCD. Among infliximab initiators, there was no observed difference in clinical outcomes or drug levels, perhaps due to weight-based dosing and/or greater use of proactive drug monitoring.
- |||||||||| tofacitinib / Generic mfg.
Journal: Tofacitinib for Refractory Uveitis and Scleritis in Children: A Case Series. (Pubmed Central) - Mar 5, 2024 Results from this study will provide valuable information regarding the relationships between physician data, wearable data, and ePROs in patients newly initiating an RA treatment, and demonstrate the feasibility of digital data capture for Remote Patient Monitoring of patients with rheumatic disease. The mean BCVA at presentation was 0.62?
- |||||||||| Humira (adalimumab) / AbbVie
Journal: An Overview of Adalimumab Therapy for Ankylosing Spondylitis. (Pubmed Central) - Feb 28, 2024 However, the conclusion emphasizes the need for further studies with extended follow-up durations to ascertain the long-term efficacy and safety of adalimumab in AS management. This systematic review provides valuable insights supporting the use of adalimumab in the treatment of AS and underscores the importance of ongoing investigations into its long-term effects to optimize its clinical utilization in AS patients.
- |||||||||| Remicade (infliximab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Enrollment closed, Trial completion date, Trial primary completion date: STARA: Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis (clinicaltrials.gov) - Feb 28, 2024 P4, N=290, Active, not recruiting, This systematic review provides valuable insights supporting the use of adalimumab in the treatment of AS and underscores the importance of ongoing investigations into its long-term effects to optimize its clinical utilization in AS patients. Unknown status --> Active, not recruiting | Trial completion date: Aug 2020 --> Aug 2024 | Trial primary completion date: Jun 2020 --> Jun 2024
- |||||||||| Humira (adalimumab) / AbbVie
Journal: Drug Retention Time of Immunosuppressive Therapy in Behcet's Uveitis. (Pubmed Central) - Feb 27, 2024 Over time, patients were switched from Cyclosporin to Adalimumab earlier in the disease course due to poorer tolerance of adverse events. Adalimumab's drug retention time was found to be similar to and possibly better than cDMARDs in patients with BU, who often suffer from vision-threatening disease at first presentation.
- |||||||||| Review, Journal: Integrating Nanotechnological Advancements of Disease-Modifying Anti-Rheumatic Drugs into Rheumatoid Arthritis Management. (Pubmed Central) - Feb 24, 2024
Biologic DMARDs (bDMARDs) like infliximab, rituximab, etanercept, adalimumab, tocilizumab, certolizumab pegol, and abatacept have greater effectiveness with fewer adverse effects in comparison to non-biologic DMARDs...The main focus of this review article is to highlight the potential role of nanotechnology in the drug delivery of DMARDs for increasing solubility, dissolution, and bioavailability for the improved management of RA. This article also focusses on the different aspects of nanoparticles like their applications in biologics, biocompatibility, body clearance, scalability, drug loading, and stability issues.
- |||||||||| Long-Term Adverse Event Risks of Systemic Janus Kinase (JAK) Inhibitors versus Traditional Immunomodulators (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 2)) - Feb 20, 2024 - Abstract #AAD2024AAD_3314;
Our evaluation encompassed several JAK inhibitors commonly used for dermatologic conditions, such as tofacitinib, baricitinib, upadacitinib, ruxolitinib, as well as traditional immunomodulators, including cyclosporine, methotrexate, etanercept, adalimumab, and systemic steroids. These findings provide valuable insights into the safety profile of JAK inhibitors and have significant implications for guiding the management of dermatologic conditions that necessitate the use of JAK inhibitors or traditional immunomodulators.
- |||||||||| Bimzelx (bimekizumab) / UCB
Bimekizumab effectiveness in the treatment of palmoplantar psoriasis: a case series () - Feb 20, 2024 - Abstract #AAD2024AAD_3006; These findings further support bimekizumab as a promising tool for treating palmoplantar psoriasis, highlighting its potential to address the unmet therapeutic needs in this challenging population. The combination of efficacy, speed, durability, posology, and safety of bimekizumab translates into better outcomes for the patient, consistently seen in both clinical trials and real-world setting.
- |||||||||| Bimzelx (bimekizumab) / UCB
Bimekizumab efficacy and safety through 4 years in moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 1)) - Feb 20, 2024 - Abstract #AAD2024AAD_2973; Introduction: Clinical improvements through Week (Wk)152, with no unexpected safety findings, were previously reported with bimekizumab (BKZ) in the BE SURE phase 3 trial and BE BRIGHT open-label extension.[1,2] In BE SURE, patients with moderate to severe plaque psoriasis were randomized 1:1:1 to either BKZ 320mg every 4 weeks (Q4W) to Wk16 then Q8W to Wk56 (BKZ Q4W/Q8W), BKZ Q4W to Wk56 (Q4W/Q4W), or adalimumab (ADA) 40mg Q2W to Wk24 then BKZ Q4W to Wk56 (ADA/BKZ).[1] At Wk56, patients could enroll in BE BRIGHT to receive open-label BKZ Q4W or Q8W;[3] all received BKZ Q8W from Wk104/next visit. Through 4 years, clinical improvements with BKZ were maintained and BKZ was well-tolerated with no unexpected safety findings.[1,2]
- |||||||||| Humira (adalimumab) / AbbVie
Biologic Therapy for Psoriasis and Risk of Malignancy- A Single-Center Retrospective Cohort Study () - Feb 20, 2024 - Abstract #AAD2024AAD_2961; In the biologic-exposed group, patients exposed to adalimumab had the highest incidence of both NMSC and systemic malignancy... In the overall assessment of the selected population, we found no significant difference in cancer incidence in patients treated with topical versus biologic therapy for psoriasis.
|